{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001660","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.204840+00:00","generated_at":"2026-06-08T16:29:49.050506+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Scholar Rock Q3 net loss $42.4M; SAPPHIRE enrollment complete, topline Q4 2024","bullets":["Net loss $42.4M (vs $43.3M YoY); no revenue; cash $218.6M + $92.5M Oct offering extends runway into H2 2025.","Completed enrollment of Phase 3 SAPPHIRE trial for apitegromab in SMA; topline data expected Q4 2024.","Expanding into cardiometabolic with SRK-439; plans Phase 2 trial with apitegromab + GLP-1 RA in 2024.","Phase 1 DRAGON trial of SRK-181 showed 21.4% ORR in ccRCC; enrollment completion in Dec 2023.","Completed $98M public offering in October 2023; proceeds support pipeline expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001660","json":"https://secwatch.observer/filing/0001157523-23-001660.json","markdown":"https://secwatch.observer/filing/0001157523-23-001660.md","text":"https://secwatch.observer/filing/0001157523-23-001660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323001660/0001157523-23-001660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323001660/a53761938.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:29:49.050506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88a6384507108f2cf28bbabe518af26bf311ee0e","claim":"Scholar Rock Holding Corp reported third quarter ended September 30, 2023 results: net income $42.4 million.","evidence_excerpt":"For the quarter ended September 30, 2023, net loss was $42.4 million compared to a net loss of $43.3 million for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323001660/0001157523-23-001660-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$42.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}